Please provide your email address to receive an email when new articles are posted on . Researchers reviewed the efficacy of ravulizumab based on 2-year data from two phase 3, single-arm studies. eGFR ...

Please provide your email address to receive an email when new articles are posted on . Registry data showed efficacy of ravulizumab was similar to that of eculizumab. No unexpected adverse events ...

The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 ...

The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic ...

- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

Alexion announced that results from its Phase 2 study of Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy. The ...

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...

Researchers from the University of Newcastle, UK, have identified a novel genetic change that causes one form of atypical hemolytic uremic syndrome (aHUS) a rare, chronic disease that causes kidney ...

(RTTNews) - Alexion Pharmaceuticals Inc. (ALXN) said Friday that Japan has approved Ultomiris or ravulizumab for adults and children living with atypical hemolytic uremic syndrome or aHUS. atypical ...